Related Experiment Video

Updated: Sep 13, 2025

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy
06:28

E-Patient Counseling Trial E-PACO: Computer Based Education versus Nurse Counseling for Patients to Prepare for Colonoscopy

Published on: August 1, 2019

8.4K

Tackling control risk problems in non-inferiority trials

Ian R White1, Matteo Quartagno1, Abdel G Babiker1

  • 1MRC Clinical Trials Unit at UCL, London, UK.

BMJ Medicine
|August 4, 2025
PubMed

Insights

Non-inferiority trials assess new treatments against standard care. This study addresses control risk challenges, offering methods to ensure trial power and interpretability for reliable clinical evidence.

Area of Science:

  • Clinical Trials Methodology
  • Biostatistics
  • Evidence-Based Medicine

Background:

  • Non-inferiority trials compare new interventions to standard care, particularly when the new option offers benefits like reduced toxicity or cost.
  • The statistical power and interpretability of these trials are highly sensitive to the control risk, defined as the outcome frequency in the standard care group.
  • Challenges arise when control risk is unexpectedly low or high, potentially rendering trials underpowered or uninterpretable.

Purpose of the Study:

  • To identify and address critical issues related to control risk in non-inferiority trial design and analysis.
  • To provide practical strategies for maintaining statistical power and ensuring the interpretability of non-inferiority trial results.
  • To guide researchers in selecting appropriate effect measures and adapting trial designs to potential variations in control risk.

Main Methods:

  • The study outlines two primary challenges concerning control risk in non-inferiority trials.
  • It proposes two key strategies: 1) careful selection of the effect measure for the non-inferiority margin, considering clinical context and sample size implications, and 2) proactive planning for potential deviations in observed control risk from the design-stage estimates.
  • Statistical principles for adapting the non-inferiority margin during trial analysis are presented.

Main Results:

  • The choice of effect measure significantly impacts the required sample size, influencing trial power.
  • Demonstrates how different effect measures can lead to either smaller or larger sample size requirements.
  • Provides a statistically sound framework for adjusting the non-inferiority margin in the analysis phase to accommodate observed control risk variations.

Conclusions:

  • Careful consideration of the effect measure and its relation to control risk is crucial for designing adequately powered and interpretable non-inferiority trials.
  • Investigators must anticipate and plan for potential discrepancies between anticipated and observed control risks.
  • Statistically principled adaptation of the non-inferiority margin during analysis is essential for robust trial outcomes.
Keywords:
Clinical trialResearch designStatistics

More Related Videos

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

10.8K
An R-Based Landscape Validation of a Competing Risk Model05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.2K

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
174
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...
155
Blinding01:11

Blinding

Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
2.6K
Controls in Experiments01:13

Controls in Experiments

When conducting an experiment, it is crucial to have control to reduce bias and accurately measure the dependent variables. It also marks the results more reliable. Controls are elements in an experiment that have the same characteristics as the treatment groups but are not affected by the independent variable. By sorting these data into control and experimental conditions, the relationship between the dependent and independent variables can be drawn. A randomized experiment always includes a...
11.2K
Confounding in Epidemiological Studies01:27

Confounding in Epidemiological Studies

Confounding in statistical epidemiology represents a pivotal challenge, referring to the distortion in the perceived relationship between an exposure and an outcome due to the presence of a third variable, known as a confounder. This variable is associated with both the exposure and the outcome but is not a direct link in their causal chain. Its presence can lead to erroneous interpretations of the exposure's effect, either exaggerating or underestimating the true association. This...
262
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
347